New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:02 EDTBAXBaxter presents efficacy and safety data on VIVIA system at ERA-EDTA Congress
Baxter International announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process in Europe, December 2013. The first in-human study was a prospective, single arm clinical study (Abstract #SP415) conducted in haemodialysis centres in the United States, in which 22 patients received four HD treatments with the VIVIA HD system every week for 10 weeks. The mean duration of each HD treatment was 3.8 hours. A mean weekly standard measure of urea clearance and dialysis adequacy, was 2.97. No device-related serious adverse events occurred during the study. The feasibility of multiple use of the same dialyser on the same patient was also established.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:36 EDTBAXInfectious Diseases Society of America to hold a conference
Subscribe for More Information
September 30, 2015
09:29 EDTBAXBaxter agrees to add Third Point representative to board
Subscribe for More Information
09:24 EDTBAXThird Point reaches standstill pact with Baxter, reports 9.9% stake
09:02 EDTBAXBaxter appoints Munib Islam to board; announces agreement with Third Point
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use